News & Events
BioLamina and Cytochroma partner to accelerate reliable New Approach Methodologies aligned with FDA Moderniziation Act 2.0
Stockholm, Sweden and Edinburgh, UK, 28 May 2026 BioLamina and Cytochroma partner to accelerate reliable New Approach Methodologies aligned […]
Swedish company BioLamina to enable next-generation cell therapies for serious chronic diseases with €20 million EIB commitment
Sundbyberg, April 16, 2026 Swedish company BioLamina to enable next-generation cell therapies for serious chronic diseases with €20 million EIB co […]
Cell X Technologies and BioLamina enter a collaboration to advance standardization in iPSC-based therapeutics
Sundbyberg, September 29, 2025 Cell X Technologies and BioLamina enter a collaboration to advance standardization in iPSC-based therapeutics BioLami […]
-
Publications July 17, 2026
Recreating human hypothalamic development using defined Biolaminin® substrates
The hypothalamus is the central control center for appetite and energy balance, integrating hormonal signals that regulate food intake and metabolis […]
-
Publications July 14, 2026
Engineering physiologically relevant renal epithelial models through basement membrane mimicry
Human renal proximal tubular epithelial cells (RPTECs) are widely used as in vitro models for studying kidney biology and supporting the development […]
-
Publications July 14, 2026
Coordinated extracellular matrix signaling regulates local translation during axon guidance
During the development of the nervous system, growing axons rely on specialized structures known as growth cones to navigate toward their correct […]
-
Publications July 2, 2026
New insights into astrocyte maturation during spinal cord development
The spinal cord is composed of both gray and white matter, with white matter containing axonal tracts responsible for transmitting sensory and […]
-
Publications July 2, 2026
Animal component-free macrophage differentiation using Biolaminin® 521
Macrophages are essential immune cells that play central roles in maintaining tissue health and coordinating inflammatory responses. Because of thes […]
-
Publications July 2, 2026
Efficient generation of highly purified pancreatic islets across multiple stem cell lines
Human pluripotent stem cell (hPSC)-derived pancreatic islets show significant promise for cell replacement therapies in type 1 diabetes, but the cur […]
-
Publications June 26, 2026
Advancing stem cell-derived liver implants toward clinical translation using defined Biolaminin® matrices
This study highlights the importance of chemically defined extracellular matrix environments for translating stem cell-derived tissue engineering te […]
-
Featured May 28, 2026
BioLamina and Cytochroma partner to accelerate reliable New Approach Methodologies aligned with FDA Moderniziation Act 2.0
Stockholm, Sweden and Edinburgh, UK, 28 May 2026 BioLamina and Cytochroma partner to accelerate reliable New Approach Methodologies aligned […]
-
Featured April 17, 2026
Swedish company BioLamina to enable next-generation cell therapies for serious chronic diseases with €20 million EIB commitment
Sundbyberg, April 16, 2026 Swedish company BioLamina to enable next-generation cell therapies for serious chronic diseases with €20 million EIB co […]
-
Publications February 2, 2026
Biolaminin 521 supports animal origin-free hESC-RPE differentiation and retinal rescue
This study demonstrates that combining a fully defined, animal origin-free culture medium with a physiologically relevant extracellular matrix is ke […]
-
Publications December 10, 2025
Biolaminin®-functionalized Biosilk scaffolds model dopaminergic neurogenesis in ventral midbrain organoids
By using a Biolaminin 111–functionalized Biosilk scaffold, the system produces organoids with stable cell-type composition, reliable dopaminergic […]
-
Publications December 8, 2025
Biosilk/Biolaminin® system supports long-term, uniform 3D neural tissue development
Biosilk and Biolaminin 521 enabled centimeter-scale, channel-permeated 3D cultures that differentiated uniformly into neuroectoderm followed by furt […]
-
Publications December 5, 2025
Biosilk recreates native tissue properties in 3D culture
Biosilk brings 3D culture closer to native tissue biology by providing an ECM-like microfiber architecture that supports firm cell attachment, sprea […]
-
Publications November 13, 2025
Laminin-augmented extracellular matrix improves human brain reconstruction
Brain organoids are valuable for modeling human brain development and disease but often lack the complex extracellular matrix (ECM) cues needed for […]
-
Featured September 30, 2025
Cell X Technologies and BioLamina enter a collaboration to advance standardization in iPSC-based therapeutics
Sundbyberg, September 29, 2025 Cell X Technologies and BioLamina enter a collaboration to advance standardization in iPSC-based therapeutics BioLami […]
-
Featured September 4, 2025
Pluristyx and BioLamina Announce Strategic Partnership to Accelerate Development of Stem Cell-Based Therapies
Sundbyberg, September 4, 2025 Pluristyx and BioLamina Announce Strategic Partnership to Accelerate Development of Stem Cell-Based Therapies Pluristy […]